Quantcast

Latest Prasugrel Stories

2011-05-11 07:30:00

SAN DIEGO, May 11, 2011 /PRNewswire/ -- Accumetrics, Inc., marketer of the VerifyNow System, the first rapid and easy-to-use point-of-care diagnostic system for measuring platelet reactivity to multiple antiplatelet agents, announced today that the company has signed a national distribution agreement with Cardinal Health, Inc. to distribute the VerifyNow System to hospitals, health systems and independent laboratories throughout the United States. The VerifyNow System is widely used by...

2011-03-29 12:34:00

PARSIPPANY, N.J. and INDIANAPOLIS, March 29, 2011 /PRNewswire/ -- Oral antiplatelet therapy Effient® (prasugrel) has been added to the updated clinical practice guidelines as a Class I recommended treatment option for patients undergoing percutaneous coronary intervention (PCI) after experiencing heart-related chest pain at rest (unstable angina) or non-ST segment elevation myocardial infarction (NSTEMI). NSTEMI is a type of heart attack that that does not need to be...

2011-03-15 15:22:00

SAN DIEGO, March 15, 2011 /PRNewswire/ -- Accumetrics, Inc., developer of the VerifyNow® System, the first rapid and easy-to-use point-of-care system for measuring platelet reactivity to multiple antiplatelet agents, announced today that the primary results of the GRAVITAS trial have been published in The Journal of the American Medical Association(1). First presented at the American Heart Association's Annual Scientific Sessions in November 2010, the results refute a...

2011-03-09 07:50:00

SAN DIEGO, March 9, 2011 /PRNewswire/ -- Accumetrics, Inc., a privately-held developer and marketer of the VerifyNow® System, the first rapid and easy-to-use point-of-care system for measuring platelet reactivity to multiple antiplatelet agents, announced today that new Guidelines were recently published in The Annals of Thoracic Surgery that include point-of-care testing for platelet reactivity as a new recommendation for preoperative patient assessment(1). Coronary...

2010-12-07 07:30:00

SAN DIEGO, Dec. 7, 2010 /PRNewswire/ -- Accumetrics, Inc., a privately-held developer and marketer of the VerifyNow® System, the first rapid and easy-to-use point-of-care system for measuring platelet reactivity to multiple antiplatelet agents, closes 2010 with continued positive medical community and industry support surrounding the importance of measuring response to antiplatelet therapy. The Company achieved several important milestones during 2010, including...

2010-11-16 09:00:00

CHICAGO, Nov. 16, 2010 /PRNewswire-FirstCall/ -- New results from an observational substudy from TRITON-TIMI 38 presented today at the American Heart Association (AHA) Scientific Sessions annual meeting showed that patients treated with Effient® (prasugrel) prior to coronary artery bypass graft surgery (CABG) had a reduced overall mortality rate compared to patients treated with Plavix® (clopidogrel) (2.3 percent versus 8.7 percent respectively,...

2010-11-16 09:00:00

CHICAGO, Nov. 16, 2010 /PRNewswire-FirstCall/ -- New results from an observational substudy from TRITON-TIMI 38 presented today at the American Heart Association (AHA) Scientific Sessions annual meeting showed that patients treated with Efient®/Effient® (prasugrel) prior to coronary artery bypass graft surgery (CABG) had a reduced overall mortality rate compared to patients treated with Plavix® (clopidogrel) (2.3 percent versus 8.7...

2010-11-16 08:05:00

SAN DIEGO, Nov. 16, 2010 /PRNewswire/ -- Accumetrics, Inc., developer and marketer of the VerifyNow® System, today announced that the GRAVITAS (Gauging Responsiveness With A VerifyNow Assay-Impact On Thrombosis And Safety) Trial found that in patients with high residual platelet reactivity, doubling the maintenance dose of clopidogrel did not reduce the risk of further ischemic events after percutaneous coronary intervention (PCI). The study also reported that patients...

2010-09-16 10:31:00

INDIANAPOLIS and TOKYO, Sept. 16 /PRNewswire/ -- In a Phase II study, Acute Coronary Syndrome (ACS) patients on maintenance clopidogrel/aspirin therapy who were switched to prasugrel (Efient® - either 10 mg maintenance dose [MD] or 60 mg loading dose [LD] followed by 10 mg MD) plus aspirin demonstrated a statistically significant greater reduction in Maximal Platelet Aggregation (MPA) after one week when compared to patients who remained on maintenance therapy (MD) with...

2010-09-13 15:24:00

PARSIPPANY, N.J. and INDIANAPOLIS, Sept. 13 /PRNewswire-FirstCall/ -- A study evaluating the level of platelet aggregation achieved after switching from Plavix® (clopidogrel) 75 mg once-daily maintenance dosing plus aspirin to Effient® (prasugrel) 10 mg once-daily maintenance dosing (MD) in patients with acute coronary syndrome (ACS) was published today in the Journal of the American College of Cardiology. In this Phase II study, ACS patients who were...


Word of the Day
penuche
  • A fudgelike confection of brown sugar, cream or milk, and chopped nuts.
'Penuche' is a variant of 'panocha,' a coarse grade of sugar made in Mexico. 'Panocha' probably comes from the Spanish 'panoja, panocha,' ear of grain.
Related